Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
DC CAFC
First Claim
Patent Images
1. An isolated human monoclonal antibody that binds to an epitope on PSCK9, wherein the epitope comprises at least one of amino acid residues S123, E129, A311, D313, or D337 of SEQ ID NO:
- 1, and wherein the monoclonal antibody blocks binding of PCSK9 to LDLR.
1 Assignment
Litigations
0 Petitions
Accused Products
Abstract
Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
-
Citations
25 Claims
-
1. An isolated human monoclonal antibody that binds to an epitope on PSCK9, wherein the epitope comprises at least one of amino acid residues S123, E129, A311, D313, or D337 of SEQ ID NO:
- 1, and wherein the monoclonal antibody blocks binding of PCSK9 to LDLR.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)
-
16. An isolated human monoclonal antibody that binds to human PCSK9 having an amino acid sequence of SEQ ID NO:
- 1 at one or more of amino acid residues S123, E129, A311, D313, or D337 of SEQ ID NO;
1, and wherein the monoclonal antibody blocks binding of PCSK9 to LDLR. - View Dependent Claims (17, 18, 19, 20, 21, 22, 23, 24, 25)
- 1 at one or more of amino acid residues S123, E129, A311, D313, or D337 of SEQ ID NO;
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
Litigation Data
-
Current AssigneeAmgen Inc.
-
Original AssigneeAmgen Inc.
-
InventorsJackson, Simon Mark, Walker, Nigel Pelham Clinton, Piper, Derek Evan, Shen, Wenyan, King, Chadwick Terence, Ketchem, Randal Robert, Mehlin, Christopher, Carabeo, Teresa Arazas
-
Primary Examiner(s)WEN, SHARON X
-
Application NumberUS14/261,063Publication NumberTime in Patent Office187 DaysField of SearchNoneUS Class Current530/388.26CPC Class CodesA61K 2039/505 comprising antibodiesA61K 2300/00 Mixtures or combinations of...A61K 31/22 of acyclic acids, e.g. prav...A61K 31/366 having six-membered rings, ...A61K 31/40 having five-membered rings ...A61K 31/405 Indole-alkanecarboxylic aci...A61K 31/44 Non condensed pyridines; Hy...A61K 31/47 Quinolines; IsoquinolinesA61K 31/505 Pyrimidines; Hydrogenated p...A61K 31/66 Phosphorus compoundsA61K 39/395 Antibodies agglutinins A61K...A61K 39/3955 against proteinaceous mater...A61K 45/06 Mixtures of active ingredie...A61P 25/28 for treating neurodegenerat...A61P 3/00 Drugs for disorders of the ...A61P 3/06 AntihyperlipidemicsA61P 43/00 Drugs for specific purposes...A61P 7/00 Drugs for disorders of the ...A61P 9/00 Drugs for disorders of the ...A61P 9/10 for treating ischaemic or a...View All
